Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

AIM ImmunoTech Inc.

NYSE: AIM · Life Sciences · 3 alerts · CIK 946644

Share price
$0.1310Close, Nov 16
Market cap
$5.23M
Shares outstanding
39.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All AIM ImmunoTech Inc. filings on SEC EDGAR ↗

4:36 PM ET 10-Q
Financial Results

AIM ImmunoTech Q3 2026 Results: Net Loss of $3.14M, Loss Narrows

AIM ImmunoTech reported a net loss of $9.95 million for the nine months ended September 30, 2026, compared to $9.78 million in the prior year. The company significantly strengthened its balance sheet through equity offerings and warrant exercises, increasing total assets to $9.75 million and achieving a positive stockholders' equity of $7.08 million.

Key figure
Net loss $3.14M
9:15 AM ET 8-K
Investor Presentation

AIM ImmunoTech Investor Presentation

AIM ImmunoTech Inc. has released a new corporate presentation titled 'The Ampligen Opportunity' along with a corresponding press release. The presentation outlines the company's strategic objectives and the clinical potential of its lead drug candidate, Ampligen, particularly in treating pancreatic cancer.

4:40 PM ET 8-K
Loan & Debt

AIM ImmunoTech Debt Financing Update with Streeterville Capital, LLC

AIM ImmunoTech entered into exchange agreements with Streeterville Capital to convert approximately $400,000 of an existing November 2025 promissory note into 1,749,434 shares of common stock. The conversion was executed at an average price of approximately $0.228 per share following prior stockholder approval for the debt satisfaction.

Counterparty
Streeterville Capital, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.